Drug Trial Radar · NCT06770439
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Apr 18, 2025
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase II study to evaluate the safety, tolerability and efficacy of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer, including Part1 (safe lead-in phase) and Part2 (extension phase). In part1, patients with CLDN18.2-positive advanced pancreatic adenocarcinoma who had or had not previously received systemic therapy were treated with chemotherapy in IBI343 with AG regimen (albumin paclitaxel with gemcitabine). In part2, 40 patients with CLDN18.2-positive advanced PDAC will be enrolled, 1:1 randomized to Arm A and Arm B, respectively. In Arm A, patients will receive IBI343 TBD + gemcitabine TBD + albumin-bound paclitaxel TBD; and in Arm B, patients will receive gemcitabine 1000mg / m2 d1, d8 Q3W + albumin-bound paclitaxel 125mg / m2d1, d8 Q3W treatment.
Conditions
- Advanced Pancreatic Cancers
Interventions
IBI343Drug
IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate
Gemcitabine+Albumin-bound paclitaxelDrug
Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Up to 2 years
- Adverse EventTime frame: Up to 2 years.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Zhejiang University Schlool of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
the First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.